Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 186

Sort by

Sort Order Select

Journal Articles

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Nizar J Bahlis, Suzanne Trudel, Christopher Maisel, Lisa X. Lee, Jorge Monge, Claudia Paba Prada, Sarah M. Larson, Guenther Koehne, Yogesh Jethava, Wei Dong Ma, Cristina De Nicolo, Isabel Perez-Cruz

Blood (2023) 142 (Supplement 1): 6737.

https://doi.org/10.1182/blood-2023-189700

Published: 2023

Journal Articles

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2023-174550

Published: 2023

Journal Articles

Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Anup J Devasia, Sahar Khan, Eshetu Atenafu, Harjot Vohra, Frédéric Larose, Donna Reece, Suzanne Trudel, A. Keith Stewart, Sita D. Bhella, Vishal Kukreti, Chloe Yang, Rodger E. Tiedemann, Anca Prica, Monica Monchis, Eugene Leung, Christina Zeglinski, Zubaida Mohamed, Christine Chen

Blood (2023) 142 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2023-190310

Published: 2023

Journal Articles

Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

Dor D. Abelman, Jenna Eagles, Stephanie Pedersen, Arnavaz Danesh, Danielle Croucher, Jeff P. Bruce, Stephenie D. Prokopec, Ellen N. Wei, Saumil Shah, Alli Murugesan, Anthony Reiman, Suzanne Trudel, Trevor J. Pugh

Blood (2023) 142 (Supplement 1): 4693.

https://doi.org/10.1182/blood-2023-173685

Published: 2023

Journal Articles

Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

Sahar Khan, Salman Basrai, Donna Reece, Sita D. Bhella, Vishal Kukreti, Anca Prica, A. Keith Stewart, Suzanne Trudel, Harjot Vohra, Chloe Yang, Sagi Abelson, Christine Chen

Blood (2023) 142 (Supplement 1): 760.

https://doi.org/10.1182/blood-2023-190978

Published: 2023

Journal Articles

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial

Martha L Louzada, Donna E. Reece, Arleigh McCurdy, Rami Kotb, Ibraheem Othman, Hira Mian, Toni Lin, Michael P Chu, Darrell White, Stephen Parkin, Engin Gul, Aniba Khan, Suzanne Trudel

Blood (2023) 142 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2023-174993

Published: 2023

Journal Articles

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Blood (2022) 140 (Supplement 1): 7301–7303.

https://doi.org/10.1182/blood-2022-164877

Published: 2022

Journal Articles

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje, Nizar Jacques Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Yair Levy, Michael H Tomasson, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P Chu, Cristina J. Gasparetto, Andrew P. Dalovisio, Michael Sebag, Alexander M Lesokhin

Blood (2022) 140 (Supplement 1): 388–390.

https://doi.org/10.1182/blood-2022-166494

Published: 2022

Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Blood (2022) 140 (Supplement 1): 4415–4417.

https://doi.org/10.1182/blood-2022-157547

Published: 2022

Journal Articles

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Sebastian Grosicki, Ulf-Henrik Mellqvist, Łukasz Pruchniewski, Jacob Crafoord, Suzanne Trudel, Chang-Ki Min, Darrell White, Adrian Alegre, Markus Hansson, Takashi Ikeda, Kazutaka Sunami, Eric Leip, Arthur Kudla, Gregory Finn, Youngil Koh

Blood (2022) 140 (Supplement 1): 4407–4408.

https://doi.org/10.1182/blood-2022-162738

Published: 2022

Journal Articles

Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Anup Joseph Devasia, Sahar Khan, Harminder K Paul, Frédéric Larose, Eshetu G. Atenafu, Donna E. Reece, Suzanne Trudel, A. Keith Stewart, Sita Bhella, Vishal Kukreti, Chloe Yang, Rodger E Tiedemann, Anca Prica, Monica Monchis, Eugene Leung, Susan Jomah, Zubaida Mohamed, Christine Chen

Blood (2022) 140 (Supplement 1): 10043–10044.

https://doi.org/10.1182/blood-2022-170681

Published: 2022

Journal Articles

MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody

Shaji K Kumar, Alfred L. Garfall, Suzanne Trudel, Enrique M. Ocio, Emma Scott, Lin Huang, Xuewen Ma, Yunsi Olyslager, Payal Thakkar, Lixia Pei, Christoph Heuck, Evangelos Terpos

Blood (2022) 140 (Supplement 1): 7292–7293.

https://doi.org/10.1182/blood-2022-163260

Published: 2022

Journal Articles

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

Suzanne Trudel, Arleigh McCurdy, Molei Fu, Heather J. Sutherland, Martha L Louzada, Michael P. Chu, Darrell J White, Hira S Mian, Rami Kotb, Ibraheem Othman, Moustafa Kardjadj, Engin Gul, Donna E. Reece

Blood (2022) 140 (Supplement 1): 7306–7307.

https://doi.org/10.1182/blood-2022-160445

Published: 2022

Journal Articles

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Paul G. Richardson, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, Robert Z. Orlowski, Kihyun Kim, María-Victoria Mateos, Charlotte Pawlyn, Karthik Ramasamy, Joaquín Martinez-Lopez, Alessia Spirli, Ignacio Casas-Avilés, Jing Gong, Michael Amatangelo, Jessica Katz, Paulo Maciag, Teresa Peluso, Nizar J. Bahlis

Blood (2022) 140 (Supplement 1): 1366–1368.

https://doi.org/10.1182/blood-2022-157945

Published: 2022

Journal Articles

Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

Suzanne Trudel, Nizar J. Bahlis, Andrew Spencer, Rayan Kaedbey, Paula Rodriguez Otero, Simon J Harrison, Chihunt Wong, Grant R. Goodman, Rin Nakamura, Voleak Choeurng, James Cooper, Maria-Victoria Mateos

Blood (2022) 140 (Supplement 1): 1363–1365.

https://doi.org/10.1182/blood-2022-159381

Published: 2022

Journal Articles

Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

Ashish Patel, Adam C. Smith, Esther Masih-Khan, Peace Samuel, Katherine Lajkosz, Sita Bhella, Christine I. Chen, Anca Prica, Donna E. Reece, A. Keith Stewart, Rodger E Tiedemann, Suzanne Trudel, Chloe Yang, Vishal Kukreti

Blood (2022) 140 (Supplement 1): 4354–4355.

https://doi.org/10.1182/blood-2022-167113

Published: 2022

Journal Articles

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Anca Prica, Vinita Dhir, Rachel Aitken, Harminder K Paul, Osvaldo Espin-Garcia, Sita Bhella, Christine I. Chen, Michael Crump, Robert Kridel, Vishal Kukreti, John Kuruvilla, Donna E. Reece, Rodger E Tiedemann, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 3055.

https://doi.org/10.1182/blood-2021-153120

Published: 2021

Journal Articles

Serine and Threonine Phosphorylation Marks Proteins for Degradation By Clpxp

Yue Feng, Yulia Jitkova, Harjeet Soor, Suzanne Trudel, Kaitlin Lees, Kaylen Soriano, Siavash Vahidi, Andrei Yudin, Aaron D Schimmer

Blood (2021) 138 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2021-146027

Published: 2021

Journal Articles

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel, Arleigh McCurdy, Heather J. Sutherland, Martha L Louzada, Christopher P. Venner, Hira S Mian, Rami Kotb, Ibraheem Othman, Fernando Camacho, Engin Gul, Donna E. Reece, Darrell J White, Molei Fu

Blood (2021) 138 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2021-147101

Published: 2021

Journal Articles

Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors

Danielle C Croucher, Laura M Richards, Zhihua Li, Ellen nong Wei, Xian Fang Huang, Daniel Waller, Marta Chesi, P. Leif Bergsagel, Michael Sebag, Trevor J. Pugh, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 1581.

https://doi.org/10.1182/blood-2021-151242

Published: 2021

NARROW

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Serine and Threonine Phosphorylation Marks Proteins for Degradation By Clpxp

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only